- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Fasting blood sugar predicts progression of non-culprit lesions in STEMI patients after primary PCI
![Fasting blood sugar predicts progression of non-culprit lesions in STEMI patients after primary PCI Fasting blood sugar predicts progression of non-culprit lesions in STEMI patients after primary PCI](https://medicaldialogues.in/h-upload/2022/12/08/750x450_193238-non-culprit-lesion.webp)
China: Fasting blood sugar is a valuable predictor for the progression of non-culprit lesions (NCL) in ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI), a recent study has shown. The study was featured in BMC Cardiovascular Disorders on 06 December 2022.
Primary PCI can rescue dying myocardium, improve prognosis, and reduce cardiovascular (CV) events in STEMI patients. However, recent studies have shown that non-culprit lesions may advance after PPCI, and NCL progression could significantly impact prognosis after PPCI. However, there is no clarity on the clinical correlation factors for the progression of NCL. Jian Wang from the Department of Cardiology in Xining First People's Hospital, Xining, Qinghai, China, and colleagues aimed to investigate the relationship between clinical features and the progression of non-culprit lesions in STEMI patients after primary PCI.
The authors enrolled 480 STEMI patients (57.1 ± 9.2 y) who underwent primary PCI between January 2016 and December 2017. As a treatment for culprit lesions, all patients underwent primary PCI. Angiographic and clinical follow-up was done for 12 months. Patients were divided into an NCL progression group (n=205) and a control group (n=275) based on follow-up outcomes at 12 months from angiography.
The study led to the following findings:
· In the NCL progression group, Body mass index (BMI), glycated serum albumin, fasting blood sugar (FBG), glycated hemoglobin, serum creatinine (Scr), and homocysteine levels were notably higher than those in the control group.
· A logistic regression analysis revealed that fasting blood sugar (odds ratio 1.274) and Scr (odds ratio 1.020) were independent predictors of NCL progression.
· A partial correlation analysis revealed that FBG was positively correlated with NCL progression (r = 0.231).
· A receiver operating characteristic curve demonstrated that the boundary point of FBG for predicting NCL progression was 5.715 mmol/L, the specificity was 46.4%, and the sensitivity was 74.4%.
"Findings from the study indicate that fasting blood sugar, body mass index, hemoglobin A1c, homocysteine, and glycated albumin may be clinical correlation factors for the progression of non-culprit lesions in STEMI patients after primary PCI," the researchers wrote. "Serum creatinine and FBG were independent predictors of NCL progress after primary PCI in STEMI patients."
The authors suggest the need for further randomized prospective controlled studies as the study is a single-centre retrospective analysis with a relatively small sample size and an absence of detailed intravascular imaging data.
Reference:
Wang, J., Yan, Cy., Wang, W. et al. The clinical prediction factors for non-culprit lesion progression in patients with acute ST elevation myocardial infarction after primary percutaneous coronary intervention. BMC Cardiovasc Disord 22, 529 (2022). https://doi.org/10.1186/s12872-022-02974-2
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751